Comparison of the Vasodepressor Effects of Prostacyclin and 6-oxo-prostaglandin F1alpha with Those of Prostaglandin E2 in Rats and Rabbits

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1978 Jan 1

PMID 339981

Citations 32

Authors

J M Armstrong

N Lattimer

S Moncada

J R Vane

Affiliations

Soon will be listed here.

Abstract

1 Vasodepressor effects of prostacyclin (5z-5,6-didehydro-9-deoxy-6,9alpha-epoxyprostaglandin F1) and its decomposition product 6-oxo-prostaglandin F1alpha (6-oxo-PGF1alpha) have been compared with those of prostaglandin E2 (PGE2) in anaesthetized rats and rabbits. 2 In rats intravenous prostacyclin produced hypotension and was 4--8 times more potent than PGE2 and about 128 times more potent than 6-oxo-PGF1alpha. 3 In rabbits also, intravenous prostacyclin (less than 2 microgram/kg) produced hypotension and was twice as active as PGE2 and approximately 250 times more active than 6-oxo-PGF1alpha. 4 In rats and rabbits vasodepressor responses induced by prostacyclin were similar in magnitude after either intravenous or intra-aortic administration. 5 Thus, in both species prostacyclin resembles PGE2 in producing vasodepression but does not lose activity on passage through the lungs. The results emphasize the need to consider prostacyclin in addition to PGE2 as a major determinant influencing blood pressure.

Citing Articles

Bioactive lipid regulation of platelet function, hemostasis, and thrombosis.

Stanger L, Holinstat M Pharmacol Ther. 2023; 246:108420.

PMID: 37100208 PMC: 11143998. DOI: 10.1016/j.pharmthera.2023.108420.

Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation.

Mitchell J, Shala F, Pires M, Loy R, Ravendren A, Benson J Sci Adv. 2021; 7(12).

PMID: 33741600 PMC: 7978428. DOI: 10.1126/sciadv.abf6054.

Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders.

Qian H, Luo N, Chi Y J Aging Res. 2012; 2012:121390.

PMID: 22500225 PMC: 3303603. DOI: 10.1155/2012/121390.

Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition.

Fetalvero K, Zhang P, Shyu M, Young B, Hwa J, Young R J Clin Invest. 2008; 118(12):3966-79.

PMID: 19033666 PMC: 2582928. DOI: 10.1172/JCI33800.

Use of prostaglandin I2 analog in treatment of massive hepatic necrosis associated with endothelial cell injury and diffuse sinusoidal fibrin deposition.

Fujiwara K, Mochida S, Ohno A, Arai M, Matsui A, Masaki N Dig Dis Sci. 1995; 40(1):41-7.

PMID: 7821117 DOI: 10.1007/BF02063939.

References

Cottee F, Flower R, Moncada S, Salmon J, Vane J . Synthesis of 6-keto-PGF1alpha by ram seminal vesicle microsomes. Prostaglandins. 1977; 14(3):413-23. DOI: 10.1016/0090-6980(77)90257-x. View

WHITTAKER N, Bunting S, Salmon J, Moncada S, Vane J, Johnson R . The chemical structure of prostaglandin X (prostacyclin). Prostaglandins. 1976; 12(6):915-28. DOI: 10.1016/0090-6980(76)90126-x. View

Raz A, Isakson P, Minkes M, NEEDLEMAN P . Characterization of a novel metabolic pathway of arachidonate in coronary arteries which generates a potent endogenous coronary vasodilator. J Biol Chem. 1977; 252(3):1123-6. View

Tuvemo T, Strandberg K, Hamberg M, Samuelsson B . Maintenance of the tone of the human umbilical artery by prostaglandin and thromboxane formation. Adv Prostaglandin Thromboxane Res. 1976; 1:425-8. View

Moncada S, Gryglewski R, Bunting S, Vane J . An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976; 263(5579):663-5. DOI: 10.1038/263663a0. View

Bunting S, Gryglewski R, Moncada S, Vane J . Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins. 1976; 12(6):897-913. DOI: 10.1016/0090-6980(76)90125-8. View

Armstrong J, Boura A, Hamberg M, Samuelsson B . A comparison of the vasodepressor effects of the cyclic effects of the cyclic endoperoxides PGG, and PGH2 with those of PGD2 and PGE2 in hypertensive and normotensive rats. Eur J Pharmacol. 1976; 39(2):251-8. DOI: 10.1016/0014-2999(76)90133-3. View

Moncada S, NEEDLEMAN P, Bunting S, Vane J . Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins. 1976; 12(3):323-35. DOI: 10.1016/0090-6980(76)90014-9. View

Horton E . Hypotheses on physiological roles of prostaglandins. Physiol Rev. 1969; 49(1):122-61. DOI: 10.1152/physrev.1969.49.1.122. View

10.

Strand J, Miller M, McGiff J . Biological activity of the methyl esters of prostaglandin E2 and its (15S)-15-methyl analogue. Eur J Pharmacol. 1974; 26(2):151-7. DOI: 10.1016/0014-2999(74)90221-0. View

11.

Cohen M, Sztokalo J, Hinsch E . The antihypertensive action of arachidonic acid in the spontaneous hypertensive rat and its antagonism by anti-inflammatory agents. Life Sci. 1973; 13(4):317-25. DOI: 10.1016/0024-3205(73)90223-3. View

12.

PAPANICOLAOU N, Meyer P . Inactivation of prostaglandins E 2 and A 2 on their single passage through the pulmonary vascular bed in anaesthetized rats. Rev Can Biol. 1972; 31(4):313-6. View

13.

Vane J, McGiff J . Possible contributions of endogenous prostaglandins to the control of blood pressure. Circ Res. 1975; 36(6 Suppl 1):68-75. DOI: 10.1161/01.res.36.6.68. View

14.

Ferreira S, Vane J . Prostaglandins: their disappearance from and release into the circulation. Nature. 1967; 216(5118):868-73. DOI: 10.1038/216868a0. View

15.

Moncada S, Higgs E, Vane J . Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977; 1(8001):18-20. DOI: 10.1016/s0140-6736(77)91655-5. View

16.

Dusting G, Moncada S, Vane J . Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins. 1977; 13(1):3-15. DOI: 10.1016/0090-6980(77)90037-5. View